Skip to main content

Table 1 Main patient characteristics

From: A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer

ID Age BMI Histologic Subtype Platinum Free Interval Stage Prior Treatment Lines Months of disease before treatment CT Response PET Response
01 56 24 Endometroid Resistant III 3 31 Partial Response Partial Response
02 72 19 Serous Partially sensitive IV 3 25 Progression Disease Progression Disease
03 59 25 Endometroid Resistant IV 3 23 Partial Response Complete Response
04 54 23 Serous Resistant IV 4 17 - Complete Response
05 54 21 Serous Partially sensitive IV 5 36 Partial Response Partial Response
06 53 26 Serous Resistant IV 5 53 Complete Response Complete Response
07 48 17 Serous Resistant III 3 26 Partial Response Partial Response
08 56 24 Serous Resistant III 3 9 Complete Response Complete Response
09 70 32 Serous Resistant IV 5 60 Complete Response -
10 61 28 Serous Partially sensitive III 5 68 Partial Response Progression Disease
11 66 26 Serous Resistant III 3 28 Partial Response Complete Response
12 70 20 Serous Partially sensitive III 3 37 Complete Response Complete Response
13 70 20 Serous Resistant III 3 13 Stable Disease Stable Disease
14 49 20 Serous Partially sensitive IV 3 27 Partial Response Partial Response
15 62 22 Serous Resistant IV 4 8 - -